GlobalData on MSN16h
J&J’s fully subcutaneous Tremfya shows 27.6% clinical remission in UCTremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback